{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:18:14Z","timestamp":1790835494456,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.revmed.2021.02.005","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T10:10:01Z","timestamp":1614679801000},"page":"722-728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["L\u2019axe CD40-CD40L\u00a0: implications actuelles et futures en immunologie clinique"],"prefix":"10.1016","volume":"42","author":[{"given":"G.","family":"Vial","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gensous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Duffau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2021.02.005_bib0315","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/eji.1830221226","article-title":"Cloning of TRAP, a ligand for CD40\u00a0on human T cells","volume":"22","author":"Graf","year":"1992","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0320","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0609.2004.00342.x","article-title":"Analysis of serum soluble CD40\u00a0ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: platelet is a major source of serum sCD40L","volume":"74","author":"Nagasawa","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0325","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.CIR.0000028962.04520.01","article-title":"Platelet-derived CD40L: the switch-hitting player of cardiovascular disease","volume":"106","author":"Andr\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2021.02.005_bib0330","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1160\/TH09-01-0029","article-title":"The multi-functionality of CD40L and its receptor CD40\u00a0in atherosclerosis","volume":"102","author":"Lievens","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.revmed.2021.02.005_bib0335","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40\u00a0ligand","volume":"67","author":"van Kooten","year":"2000","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0340","doi-asserted-by":"crossref","first-page":"36083","DOI":"10.1074\/jbc.M113.506220","article-title":"CD154\u00a0is released from T-cells by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17\u00a0in a CD40\u00a0protein-dependent manner","volume":"288","author":"Yacoub","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.revmed.2021.02.005_bib0345","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1538-7836.2010.03837.x","article-title":"CD40\u00a0ligand shedding is regulated by interaction between matrix metalloproteinase-2\u00a0and platelet integrin alpha(IIb)beta(3)","volume":"8","author":"Choi","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2021.02.005_bib0350","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.revmed.2021.02.005_bib0355","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0952-7915(97)80078-7","article-title":"Functions of CD40\u00a0on B cells, dendritic cells and other cells","volume":"9","author":"van Kooten","year":"1997","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0360","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2567.2000.00074.x","article-title":"Fortifying B cells with CD154: an engaging tale of many hues","volume":"100","author":"Gordon","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.revmed.2021.02.005_bib0365","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","article-title":"CD40\u00a0and CD154\u00a0in cell-mediated immunity","volume":"16","author":"Grewal","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0370","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/35393","article-title":"CD40\u00a0ligand on activated platelets triggers an inflammatory reaction of endothelial cells","volume":"391","author":"Henn","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2021.02.005_bib0375","article-title":"The CD40-CD40L dyad as immunotherapeutic target in cardiovascular disease","author":"Bosmans","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.revmed.2021.02.005_bib0380","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1172\/JCI7014","article-title":"The soluble CD40\u00a0ligand sCD154\u00a0in systemic lupus erythematosus","volume":"104","author":"Kato","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2021.02.005_bib0385","doi-asserted-by":"crossref","first-page":"47ra63","DOI":"10.1126\/scitranslmed.3001001","article-title":"Platelet CD154\u00a0potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"2","author":"Duffau","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.revmed.2021.02.005_bib0390","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2003-07-2367","article-title":"Platelet-associated CD154\u00a0in immune thrombocytopenic purpura","volume":"105","author":"Solanilla","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2021.02.005_bib0395","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/annrheumdis-2019-216588","article-title":"Salivary gland epithelial cells from patients with Sj\u00f6gren's syndrome induce B-lymphocyte survival and activation","volume":"79","author":"Rivi\u00e8re","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2021.02.005_bib0400","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/sji.12121","article-title":"Upregulation of membrane-bound CD40L on CD4+ T cells in women with primary Sj\u00f6gren's syndrome","volume":"79","author":"Belkhir","year":"2014","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0405","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10238-019-00568-5","article-title":"Assessment of CD40\u00a0and CD40L expression in rheumatoid arthritis patients, association with clinical features and DAS28","volume":"19","author":"Rom\u00e1n-Fern\u00e1ndez","year":"2019","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.revmed.2021.02.005_bib0410","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1136\/gut.52.10.1435","article-title":"Activated platelets are the source of elevated levels of soluble CD40\u00a0ligand in the circulation of inflammatory bowel disease patients","volume":"52","author":"Danese","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2021.02.005_bib0415","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.2174\/138161212802481237","article-title":"Atherosclerosis as an inflammatory disease","volume":"18","author":"Tuttolomondo","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.revmed.2021.02.005_bib0420","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1753425917739681","article-title":"Prospects for modulating the CD40\/CD40L pathway in the therapy of the hyper-IgM syndrome","volume":"24","author":"Meng","year":"2018","journal-title":"Innate Immun"},{"key":"10.1016\/j.revmed.2021.02.005_bib0425","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.175.4.1091","article-title":"Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help)","volume":"175","author":"Lederman","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.revmed.2021.02.005_bib0430","doi-asserted-by":"crossref","first-page":"8789","DOI":"10.1073\/pnas.94.16.8789","article-title":"CTLA4-Ig and anti-CD40\u00a0ligand prevent renal allograft rejection in primates","volume":"94","author":"Kirk","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.revmed.2021.02.005_bib0435","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40\u00a0ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2021.02.005_bib0440","first-page":"95","article-title":"Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus","volume":"28","author":"Davis","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0445","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.10681","article-title":"Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kalunian","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2021.02.005_bib0450","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2008.07039.x","article-title":"The effect of anti-CD40\u00a0ligand in immune thrombocytopenic purpura","volume":"141","author":"Patel","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0455","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood-2003-06-2167","article-title":"Effect of a single injection of humanized anti-CD154\u00a0monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura","volume":"103","author":"Kuwana","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2021.02.005_bib0460","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/978-0-387-89520-8_2","article-title":"Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges","volume":"647","author":"Law","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0465","first-page":"725","article-title":"IDEC-131. IDEC\/Eisai","volume":"3","author":"Dumont","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.revmed.2021.02.005_bib0470","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/01.TP.0000116392.72152.75","article-title":"Monotherapy with the novel human anti-CD154\u00a0monoclonal antibody ABI793\u00a0in rhesus monkey renal transplantation model","volume":"77","author":"Kanmaz","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.revmed.2021.02.005_bib0475","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.TP.0000116563.72763.83","article-title":"Efficacy and safety of ABI793, a novel human anti-human CD154\u00a0monoclonal antibody, in cynomolgus monkey renal allotransplantation","volume":"77","author":"Schuler","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.revmed.2021.02.005_bib0480","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/annrheumdis-2019-eular.5529","article-title":"FRI0195\u00a0efficacy and safety of dapirolizumab pegol (DZP) in patients with moderately to severely active systemic lupus erythematosus (SLE): a randomised, placebo (PBO)-controlled STUDY","volume":"78","author":"Furie","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2021.02.005_bib0485","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/ajt.14197","article-title":"Fc-Silent anti-CD154\u00a0domain antibody effectively prevents nonhuman primate renal allograft rejection","volume":"17","author":"Kim","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.revmed.2021.02.005_bib0490","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/bph.14897","article-title":"The enhanced immunopharmacology of VIB4920, a novel Tn3\u00a0fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys","volume":"177","author":"Nicholson","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0495","first-page":"11","article-title":"A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity","author":"Karnell","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.revmed.2021.02.005_bib0500","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1160\/TH04-12-0774","article-title":"The role of CD40\u00a0in CD40L- and antibody-mediated platelet activation","volume":"93","author":"Langer","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.revmed.2021.02.005_bib0505","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1136\/annrheumdis-2017-211388","article-title":"Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles","volume":"76","author":"Chamberlain","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2021.02.005_bib0510","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nm0302-247","article-title":"CD40L stabilizes arterial thrombi by a beta3\u00a0integrin\u00a0\u2013\u00a0dependent mechanism","volume":"8","author":"Andr\u00e9","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.revmed.2021.02.005_bib0515","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/0961203315574558","article-title":"First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus","volume":"24","author":"Tocoian","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2021.02.005_bib0520","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1073\/pnas.1400419111","article-title":"Blocking CD40-TRAF6\u00a0signaling is a therapeutic target in obesity-associated insulin resistance","volume":"111","author":"Chatzigeorgiou","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.revmed.2021.02.005_bib0525","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10787-018-0472-2","article-title":"Influence of corticosteroid therapy on IL-18\u00a0and nitric oxide production during Beh\u00e7et's disease","volume":"26","author":"Djaballah-Ider","year":"2018","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.revmed.2021.02.005_bib0530","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.steroids.2014.04.003","article-title":"Effects of representative glucocorticoids on TNF\u03b1- and CD40L-induced NF-\u03baB activation in sensor cells","volume":"85","author":"Cechin","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.revmed.2021.02.005_bib0535","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/096120330000900106","article-title":"Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers","volume":"9","author":"Amano","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2021.02.005_bib0540","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-017-1393-y","article-title":"Hydroxychloroquine inhibits CD154\u00a0expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling","volume":"19","author":"Wu","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.revmed.2021.02.005_bib0545","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0961203312437270","article-title":"Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort","volume":"21","author":"Willis","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2021.02.005_bib0550","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3899\/jrheum.120889","article-title":"Evaluation of serum biomarkers associated with radiographic progression in methotrexate-naive rheumatoid arthritis patients treated with methotrexate or golimumab","volume":"40","author":"Wagner","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0555","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clim.2015.03.005","article-title":"The effect of mycophenolic acid on epigenetic modifications in lupus CD4+ T cells","volume":"158","author":"Yang","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0560","doi-asserted-by":"crossref","first-page":"H2072","DOI":"10.1152\/ajpheart.00467.2010","article-title":"Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake","volume":"300","author":"Giannini","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0565","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/acr.22169","article-title":"Suboptimal inhibition of platelet cyclooxygenase 1\u00a0by aspirin in systemic lupus erythematosus: association with metabolic syndrome","volume":"66","author":"Kawai","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2021.02.005_bib0570","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2147\/DDDT.S163705","article-title":"Immature platelets and antiplatelet therapy response to aspirin in Kawasaki disease","volume":"12","author":"Pi","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.revmed.2021.02.005_bib0575","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.10.001","article-title":"Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke","volume":"25","author":"Sternberg","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.revmed.2021.02.005_bib0580","doi-asserted-by":"crossref","first-page":"521e1","DOI":"10.1016\/j.ahj.2005.10.021","article-title":"Effects of clopidogrel on soluble CD40\u00a0ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease","volume":"151","author":"Azar","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.revmed.2021.02.005_bib0585","first-page":"530","article-title":"PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin","volume":"36","author":"Willerson","year":"2009","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.revmed.2021.02.005_bib0590","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5603\/CJ.2013.0045","article-title":"Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2\u00a0diabetes and high platelet reactivity: the AVOCADO study","volume":"20","author":"Rosiak","year":"2013","journal-title":"Cardiol J"},{"key":"10.1016\/j.revmed.2021.02.005_bib0595","first-page":"105097","article-title":"The impact of clopidogrel on plasma-soluble CD40\u00a0ligand levels in systemic lupus erythematosus patients: the CLOPUS phase I\/II pilot study","author":"Vial","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2021.02.005_bib0600","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/01.CIR.0000025419.95769.F0","article-title":"Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy","volume":"106","author":"Cipollone","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2021.02.005_bib0605","first-page":"162","article-title":"Effects of statins on proinflammatory\/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort","volume":"32","author":"Willis","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2021.02.005_bib0610","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/28204","article-title":"Reduction of atherosclerosis in mice by inhibition of CD40\u00a0signalling","volume":"394","author":"Mach","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2021.02.005_bib0615","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2021.02.005_bib0310","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-med-060911-090007","article-title":"Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus","volume":"64","author":"Kahlenberg","year":"2013","journal-title":"Annu Rev Med"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866321000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866321000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:44:09Z","timestamp":1759337049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866321000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0248866321000308"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2021.02.005","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L\u2019axe CD40-CD40L\u00a0: implications actuelles et futures en immunologie clinique","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2021.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}